“In just over a year and a half we have entered into over 15 proof of concept collaborations for both human and animal health working with 7 top pharma companies and we initiated two internally funded research projects. We also have additional opportunities through our equity stakes in Novovet, Alphazyme, BDI and VLPbio.” added Mr. Marc Emalfarb.
- Our financial position remains solid with approximately $37.2 million in cash and investment-grade securities, including accrued interest. We are debt-free and we are further supported by partner funded on-going R&D collaborations. In sum, we are very well-positioned to execute..
- On July 1, 2019, Dyadic was added to the Russell Microcap® Index, which is often used by investors for passive funds and investment products and referenced as benchmarks for active investment strategies.
- On October 28, 2019, Dyadic entered into a fully funded collaboration with one of the leading animal health companies to demonstrate the C1 technology for expression and production of therapeutic proteins for companion and farm animal health diseases.
(Client, see research reports for full disclosure and disclaimer details.)
